EyePoint Pharmaceuticals, Inc. (FRA:PV3B)

Market Cap	1.02B
Revenue (ttm)	36.09M
Net Income (ttm)	-175.36M
Shares Out	n/a
EPS (ttm)	-2.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	72
Open	12.21
Previous Close	12.51
Day's Range	12.21 - 12.24
52-Week Range	3.53 - 12.54
Beta	n/a
RSI	62.18
Earnings Date	Mar 2, 2026

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related ma...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 165
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PV3B

Financial Performance

In 2024, EyePoint Pharmaceuticals's revenue was $43.27 million, a decrease of -5.97% compared to the previous year's $46.02 million. Losses were -$130.87 million, 84.9% more than in 2023.

Financial numbers in USD